Guía de diagnóstico y tratamiento de la hipertensión pulmonar: resumen de recomendaciones

…, R López-Reyes, I Otero, G Pérez-Peñate… - Archivos de …, 2018 - Elsevier
La hipertensión pulmonar es un trastorno hemodinámico definido por el aumento anómalo
de la presión arterial pulmonar, que puede presentarse en numerosas enfermedades y …

Effect of a pulmonary embolism diagnostic strategy on clinical outcomes in patients hospitalized for COPD exacerbation: a randomized clinical trial

…, A Hernando, P Ruiz-Artacho, G Pérez-Peñate… - Jama, 2021 - jamanetwork.com
Importance Active search for pulmonary embolism (PE) may improve outcomes in patients
hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD). Objective To …

Guidelines on the diagnosis and treatment of pulmonary hypertension: summary of recommendations

…, R López-Reyes, I Otero, G Pérez-Peñate… - Archivos de …, 2018 - Elsevier
… Diet: advise a daily salt intake of <5 g (equivalent to 2 g sodium), particularly in patients with
right … Pérez-Peñate has received fees from Actelion, Bayer, and Merck Sharp & Dohme, not …

Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre …

…, JA Barberá, M Lázaro, GM Perez-Penate… - The Lancet …, 2021 - thelancet.com
Background Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the
treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different …

Usefulness of cephalometry in sparing polysomnography of patients with suspected obstructive sleep apnea

G Julià-Serdà, G Pérez-Peñate… - Sleep and …, 2006 - Springer
The aim of this investigation was to evaluate the contribution of cephalometry to a statistical
model integrating clinical, physical, and oximetric variables, to reduce demands for …

Pulmonary arterial hypertension in systemic lupus erythematosus: prevalence and predictors

GM Pérez-Peñate, I Rúa-Figueroa… - The Journal of …, 2016 - jrheum.org
Objective. Pulmonary arterial hypertension (PAH) prevalence has been reported to be
between 0.5% and 17% in systemic lupus erythematosus (SLE). This study assessed PAH …

One-year continuous inhaled nitric oxide for primary pulmonary hypertension

G Pérez-Peñate, G Julià-Serdà, P Cabrera-Navarro… - Chest, 2001 - Elsevier
We describe a case of long-term administration of nitric oxide (NO) in a32-year-old man
who was admitted with exertional dyspnea and anasarca. A diagnosis of primary pulmonary …

Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension

GM Pérez-Peñate, G Juliá-Serdà… - The Journal of heart and …, 2008 - Elsevier
BACKGROUND: Inhaled nitric oxide (iNO) is a potent pulmonary vasodilator, but therapeutic
experience in patients with severe pulmonary hypertension is scarce. METHODS: Eleven …

[HTML][HTML] Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol

G Pérez Peñate, N Ochoa Parra… - Frontiers in Public …, 2022 - frontiersin.org
Introduction Pulmonary arterial hypertension (PAH) is a rare, multifactorial, chronic
condition that requires ongoing monitoring and assessment. PAHcare™ is a novel, patient-centered …

Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry

…, P Álvarez-Vega, GM Pérez-Peñate… - International Journal of …, 2019 - Elsevier
Introduction REHAP is a voluntary, observational Spanish registry of patients with pulmonary
arterial hypertension. We analyzed the experience (use and effectiveness) with inhaled …